Cytomos Overview
- Founded
- 2011
- Status
- Private
- Employees
- 8
- Latest Deal Type
- Later Stage VC
- Latest Deal Amount
- $2.13M
- Investors
- 2
Cytomos General Information
Description
Developer of a dielectric spectroscopy technology designed to assist in label-free cell analysis for biomedical research. The company's patented cell analysis technology ensures that every cell is analyzed providing granular information on individual cells and the whole sample population, facilitates automated and quantitative sample assessment, phenotypic drug discovery and stem cell therapy, enabling medical researchers to find functional endpoints that generate high-content fingerprints to prepare the right dose thereby making cell-based diagnostics efficient.
Contact Information
Website
www.cytomos.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Drug Discovery
Primary Office
- 13 Melville Street
- Edinburgh EH3 7PE
- Scotland, United Kingdom
Cytomos Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 23-Apr-2018 | $2.13M | 00.000 | 00.000 | Completed | Startup |
| 2. Early Stage VC | 16-Feb-2016 | 00000 | 00000 | 00.000 | Completed | Startup |
| 1. Angel (individual) | 15-Dec-2014 | $157K | $157K | 00000 | Completed | Startup |
Cytomos Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| Ordinary | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Ordinary | 19,800 | $0.000014 | $7.14 | $7.14 | 1x | $7.14 | 4.78% |
Cytomos Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Keith Muir Ph.D | Founder, Board Member & Chief Executive Officer |
Cytomos Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alister Minty | Self | Chairman | 000 0000 |
| Gino Miele Ph.D | Cytomos | Board Member | 000 0000 |
| Keith Muir Ph.D | Cytomos | Founder, Board Member & Chief Executive Officer | 000 0000 |
| Margaret Temple | Self | Board Member | 000 0000 |
Cytomos Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialCytomos Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Scottish Enterprise | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Archangel Investors | Angel Group | Minority | 000 0000 | 000000 0 |